Etrolizumab rhuMAb Beta7; RG7413; PRO145223|cas:1044758-60-2|西域试剂

Etrolizumab rhuMAb Beta7; RG7413; PRO145223,99.32%

产品编号：Bellancom-P9984| CAS NO：1044758-60-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P9984		￥6000.00	杭州北京（现货）
Bellancom-P9984		￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Etrolizumab rhuMAb Beta7; RG7413; PRO145223

产品介绍

Etrolizumab (rhuMAb Beta7) 是一种肠道选择性抗-β7 整合素单克隆抗体。Etrolizuma b是针对 α4β7 和 αEβ7 整合素的 β7 亚基的特异性靶向活性分子。Etrolizumab 可用于炎症性肠病 (IBD) 的研究。

生物活性

Etrolizumab (rhuMAb Beta7) is a gut-selective, anti-β7 integrin monoclonal antibody. Etrolizumab is specific targeting of the β7 subunit of α4β7 and αEβ7 integrins with K_i values of 18 nM and 1800 pM for Human α4β7 and Human αEβ7-293, respectively. Etrolizumab can be used in research of inflammatory bowel disease (IBD).

体外研究

Etrolizumab (rhuMAb Beta7) binds the β7 subunit of both α4β7 and αEβ7 integrins with high affinity, with K_d values of 18 nM, 1800 pM, 181 pM, 116 pM, 57 pM, 31.7 pM, and 25.7 pM for Human α4β7, Human αEβ7-293, Mouse α4β7-38C13, Human α4β7-293, Rabbit PBLs, Human PBLs, and Cyno PBLs, respectively.
Etrolizumab (RPMI 8866 cells and αEβ7-293 cells) blocks the interaction of α4β7 with its cognate ligands MAdCAM-1 and VCAM-1 with IC₅₀ values of 0.075 and 0.089 nM, respectively, and blocks the interaction between αEβ7 and its ligand E-cadherin with an IC₅₀ value of 3.96 nM.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Etrolizumab (rhuMAb Beta7; 5 mg/kg; i.v.; once; normal female BALB/c mice) decreases β7 integrins on T lymphocytes.
Etrolizumab (200 µg (100 µL); i.p.; once) inhibits lymphocyte homing in the CD45RB^high T cell-reconstituted SCID mouse model of colitis.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Normal female BALB/c mice (17-21 g)
Dosage:	5 mg/kg
Administration:	Intravenous injection; once
Result:	Had 98.3% of intraepithelial CD8⁺ T-cell β7 integrin receptors and 90.0% of intraepithelial CD4⁺ T-cell β7 integrin receptors after 24 h.

Animal Model:	SCID mouse model of colitis
Dosage:	200 µg (100 µL)
Administration:	Intraperitoneal injection; once
Result:	Blocked lymphocyte recruitment and homing to the inflamed colon.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Normal female BALB/c mice (17-21 g)
Dosage:	5 mg/kg
Administration:	Intravenous injection; once
Result:	Had 98.3% of intraepithelial CD8⁺ T-cell β7 integrin receptors and 90.0% of intraepithelial CD4⁺ T-cell β7 integrin receptors after 24 h.

Animal Model:	SCID mouse model of colitis
Dosage:	200 µg (100 µL)
Administration:	Intraperitoneal injection; once
Result:	Blocked lymphocyte recruitment and homing to the inflamed colon.